Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
NCT ID NCT04840264
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase II trial tests a modified combination of three chemotherapy drugs—docetaxel, oxaliplatin, and fluorouracil—in people with advanced stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) and caused a bowel blockage that cannot be surgically removed. The main goal is to see if the treatment can relieve the blockage within 60 days. The study enrolls adults aged 18 to 75 with a performance status up to 3.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel, oxaliplatin, and fluorouracil
- What this could lead to
- If successful, this could offer a way to relieve bowel blockages in advanced gastric cancer patients who cannot have surgery, potentially improving quality of life.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. Chemotherapy side effects can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
- Light-Activated therapy shows promise for tumor control without surgery
- Cancer-Fighting virus shows promise in Hard-to-Treat ovarian cancer
- New drug cocktail shows promise for tough stomach cancers